$0.77
-1.9%Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Negative working capital with limited cash reserves requires immediate attention—potential liquidity crisis if not addressed promptly.
CTOR • NASDAQ
| Citius Oncology, Inc. Balance Sheet | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
ASSETS | ||||
CURRENT ASSETS | ||||
3.9M | 112.0 | 0.0 | 0.0 | |
3.9M | 112.0 | 0.0 | 0.0 | |
22.3M | 8.3M | 0.0 | 0.0 | |
1.3M | 2.7M | 7.7M | 2.7M | |
27.5M | 11M | 7.7M | 2.7M | |
NON-CURRENT ASSETS | ||||
73.4M | 73.4M | 40M | 40M | |
73.4M | 73.4M | 40M | 40M | |
100.9M | 84.4M | 47.7M | 42.7M | |
LIABILITIES | ||||
CURRENT LIABILITIES | ||||
13.2M | 3.7M | 1.3M | 92.3K | |
13.2M | 3.7M | 1.3M | 92.3K | |
13.6M | 588.8K | 19.8M | 5.8M | |
22.7M | 28.4M | 0.0 | 0.0 | |
49.5M | 32.7M | 21M | 5.8M | |
NON-CURRENT LIABILITIES | ||||
3.8M | 3.8M | 0.0 | 0.0 | |
2.8M | 1.7M | 1.2M | 576K | |
6.6M | 5.5M | 1.2M | 576K | |
56.1M | 38.2M | 22.2M | 6.4M | |
SHAREHOLDERS' EQUITY | ||||
8.4K | 7.2K | 6.8K | 6.8K | |
108.9M | 85.4M | 43.7M | 41.7M | |
-64M | -39.3M | -18.1M | -5.4M | |
44.9M | 46.1M | 25.5M | 36.3M | |
44.9M | 46.1M | 25.5M | 36.3M | |
SUMMARY | ||||
100.9M | 84.4M | 47.7M | 42.7M | |
3.8M | 3.8M | 0.0 | 0.0 | |
-124.8K | 3.8M | 0.0 | 0.0 | |
83,513,440 | 83,513,440 | 83,513,440 | 83,513,440 |
CTOR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 01, 2026 | June 01, 2026 | 2026 | |
S-3 S-3 N/A | May 29, 2026 | May 29, 2026 | ||
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 |
Continue your CTOR research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.